Evaluation of the Safety of Relaxin in Preeclampsia

Paused · Phase 1

Conditions studied: Pre-Eclampsia

In brief

The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia

Key facts

Study ID

NCT00333307

Run by

Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

People needed

18

Starts

2006-10-01

Last updated by the study team

2010-03-16

Who can join

Age: 18 and older, up to 40. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of preeclampsia
• Hospital admission for expectant management

You may not qualify if…

• Eclampsia or history of seizures
• Vaginal bleeding
• Multifetal gestation
• Requirement for immediate delivery

Where it is running

• Central Baptist Hospital — Lexington, Kentucky, United States
• University of Cincinnati — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.